|
Let the Epic Curing Begin: Epix and Curis Earn Milestone Payments
|
Erik Mellgren |
05/05/08 |
|
No Comments
|
|
Cornerstone Buys Critical Therapeutics
|
Wade Roush |
05/02/08 |
|
No Comments
|
|
Take Two Blueberry Jelly Beans and Call Me in the Morning: Cambridge Biotech’s Best and Brightest on Show (or Not)
|
Erik Mellgren |
05/02/08 |
|
1 Comment
|
|
Sirtris Exec Says Acquisition by GlaxoSmithKline is “Great for Boston”
|
Wade Roush |
04/22/08 |
|
1 Comment
|
|
GlaxoSmithKline Scoops Up Sirtris
|
Wade Roush |
04/22/08 |
|
2 Comments
|
|
Aileron Raises $10 Million
|
Robert Buderi |
04/15/08 |
|
No Comments
|
|
ArQule Gets a New CEO
|
Wade Roush |
04/15/08 |
|
No Comments
|
|
Vertex on the Rise, Sirtris on TV, an IPO (Finally) on the Table, and More Life Sciences News
|
Rebecca Zacks |
04/02/08 |
|
No Comments
|
|
Vertex Jumps More Than 25 Percent on Hepatitis Drug Data
|
Robert Buderi |
03/31/08 |
|
No Comments
|
|
Vertex Climbs on Encouraging Early Results From Cystic Fibrosis Drug Trial
|
Rebecca Zacks |
03/27/08 |
|
No Comments
|
|
Two Highland Funds Join Forces to Lead $20 Million Funding Round for Pharmaca Retail Chain
|
Robert Buderi |
03/26/08 |
|
No Comments
|
|
Sirtris Awarded Patent
|
Wade Roush |
03/19/08 |
|
No Comments
|
|
Hydra Biosciences Feeling No Pain, Thanks to $34 Million From Advanced Technology Ventures And Others
|
Rebecca Zacks |
03/13/08 |
|
No Comments
|
|
Alnylam Touts Early Evidence of RNAi Drug Efficacy
|
Wade Roush |
02/29/08 |
|
No Comments
|
|
Biogen Bouncing Back From Tysabri Warning News
|
Rebecca Zacks |
02/28/08 |
|
1 Comment
|
|
Targanta Files for FDA Approval of Anti-MRSA Drug
|
Rebecca Zacks |
02/11/08 |
|
No Comments
|
|
GTC Biotherapeutics, Racing Against Time to Prove the Worth of “Pharming”
|
David Stipp |
02/11/08 |
|
No Comments
|
|
Hologic Grabs $82M for Drug
|
Rebecca Zacks |
01/22/08 |
|
No Comments
|
|
NitroMed Ends BiDil Marketing, Slashes Staff
|
Rebecca Zacks |
01/16/08 |
|
No Comments
|
|
Vertex Falls On Hepatitis Drug Delay Reports
|
Robert Buderi |
01/04/08 |
|
No Comments
|
|
Sepracor Licenses Epilepsy Drug
|
Robert Buderi |
01/02/08 |
|
No Comments
|
|
Altus Shares Nosedive as Agreement With Genentech Ends
|
Robert Buderi |
12/20/07 |
|
No Comments
|
|
Idera Pharmaceuticals Inks Potential $400 Million-Plus Deal with Germany’s Merck
|
Malorye Allison |
12/20/07 |
|
No Comments
|
|
For Logical Therapeutics It’s a New City and a New Approach to Anti-Inflammatory Drugs; For the CEO, It’s a Whole New Career
|
Rebecca Zacks |
12/13/07 |
|
No Comments
|
|
Biogen Idec Announces It Will Remain Independent—Says No “Definitive Offers” Received, Not Even From Icahn. Shares Plummet
|
Robert Buderi |
12/12/07 |
|
No Comments
|
|
Biogen Idec Shares Rising—But Is No News Really News?
|
Robert Buderi |
12/12/07 |
|
No Comments
|
|
GTC Drug Gets Orphan Status
|
Rebecca Zacks |
12/10/07 |
|
No Comments
|
|
Riding the Biomarker Wave: Aveo Snags Eli Lilly Deal
|
Malorye Allison |
12/05/07 |
|
No Comments
|
|
NitroMed is Feeling the Pressure but Still Betting on Marketing to Save BiDil
|
Malorye Allison |
11/28/07 |
|
No Comments
|
|
Ariad Staffs Up In Anticipation of Growth
|
Malorye Allison |
11/27/07 |
|
No Comments
|
